

Drug Monograph

Drug/Drug **Doryx™ (doxycycline hyclate) delayed-release tablet/**
Class: **Tetracyclines**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Doryx™ is now available as a delayed-release tablet containing 50 mg of specially coated pellets of doxycycline hyclate equivalent to 50 mg of doxycycline.
Manufacturer:	Mayne Pharma, Greenville, NC 27834
Indications:	Doryx™ (doxycycline hyclate) is a tetracycline-class antibiotic indicated in the following conditions or diseases: Rickettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections, anthrax including inhalational anthrax (post-exposure), alternative treatment for selected infections when penicillin is contraindicated, adjunctive therapy for acute intestinal amebiasis and severe acne, and prophylaxis of malaria.
Costs:	\$9.98 per tablet of Doryx™. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input checked="" type="checkbox"/> Under Solicitation <input type="checkbox"/> Appropriate Indications <input type="checkbox"/> Preferred Agent

Prepared By: Luke Boehmer Pharm.D.
Date: August 21, 2015